Video

Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durvalumab or Placebo plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer

Author(s):

Do-Youn Oh, MD, PhD

Do-Youn Oh, MD reviews the updated OS results of the phase 3 study, TOPAZ-1, evaluating the use of durvalumab plus GemCis versus placebo for patients with advanced biliary tract cancer (BTC).

Related Videos
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
DB-12
5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
RMC-9805
LGSOC 2024
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung
Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Related Content